Home » Stocks » TGTX

TG Therapeutics, Inc. (TGTX)

Stock Price: $28.28 USD 0.50 (1.80%)
Updated December 4, 2:48 PM EST - Market open

TGTX Stock Price Chart

Key Info

Market Cap 3.72B
Revenue (ttm) 152,000
Net Income (ttm) -230.74M
Shares Out 119.18M
EPS (ttm) -2.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $28.28
Previous Close $27.78
Change ($) 0.50
Change (%) 1.80%
Day's Open 27.92
Day's Range 27.10 - 28.28
Day's Volume 801,696
52-Week Range 7.12 - 31.10

TGTX Stock News

GlobeNewsWire - 2 days ago

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of data from a Phase 2 study evaluating umbralisib, the Company's investigation...

GlobeNewsWire - 4 days ago

Fireside chat scheduled for Tuesday, December 1, 2020 at 10:05 AM ET Fireside chat scheduled for Tuesday, December 1, 2020 at 10:05 AM ET

GlobeNewsWire - 3 weeks ago

Fireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET/ 7:20 PM GMT Fireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET/ 7:20 PM GMT

Insider Monkey - 3 weeks ago

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 823 active prominent money managers and anal...

Zacks Investment Research - 3 weeks ago

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -78.05% and -5.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the ...

GlobeNewsWire - 3 weeks ago

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2020 and recent company develop...

GlobeNewsWire - 1 month ago

UNITY-CLL: U2 significantly improved progression-free survival over obinutuzimab plus chlorambucil (HR= 0 .54, p

Zacks Investment Research - 1 month ago

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 month ago

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the com...

GlobeNewsWire - 2 months ago

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its participation at two upcoming virtual investor conferences. Michael S. Weiss, the Compan...

Benzinga - 3 months ago

TG Therapeutics (NASDAQ: TGTX) shares are trading higher on Thursday after the company announced that the FDA accepted its new drug application for its Umbralisib as a treatment for patients w...

GlobeNewsWire - 3 months ago

NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Applica...

Seeking Alpha - 3 months ago

TG Therapeutics (TGTX) CEO, Michael Weiss on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and -5.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2020 and recent company developme...

Zacks Investment Research - 4 months ago

Does TG Therapeutics (TGTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 4 months ago

TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 4 months ago

NEW YORK, July 08, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of preclinical data describing the unique immunomodulatory effects of umbrali...

GlobeNewsWire - 5 months ago

NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced...

GlobeNewsWire - 5 months ago

Presentation scheduled for Thursday, June 18, 2020, at 3:40 PM ET Presentation scheduled for Thursday, June 18, 2020, at 3:40 PM ET

GlobeNewsWire - 5 months ago

NEW YORK, June 12, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the 25th European Hematology Association (EHA) annual congress includi...

The Motley Fool - 5 months ago

The development-stage company appears to be on the path to commercial operations.

GlobeNewsWire - 5 months ago

Presentation scheduled for, Thursday, June 11, 2020, at 4:40 PM ET Presentation scheduled for, Thursday, June 11, 2020, at 4:40 PM ET

GlobeNewsWire - 6 months ago

The addition of ublituximab to ibrutinib significantly improved PFS, ORR, CR rate, and increased rates of uMRD compared with ibrutinib monotherapy

InvestorPlace - 6 months ago

With the worst of the coronavirus priced into markets, the U.S. economy is slowly reopening, serving as another boon for small-cap stocks.

Other stocks mentioned: GLUU, INSG
GlobeNewsWire - 6 months ago

NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases (“the Company”), ...

GlobeNewsWire - 6 months ago

NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases (“TG...

InvestorPlace - 6 months ago

By 2024, the biotech sector could rocket to $775 billion with plenty of long-term growth catalysts. And that's great news for biotech stocks.

Other stocks mentioned: CRSP, MRNA
GlobeNewsWire - 6 months ago

NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 56th American Society of Clinical Oncology...

GlobeNewsWire - 6 months ago

NEW YORK, May 08, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Owen A. O’Connor, MD, PhD, has joined the Company as Chief Scientific Officer. Dr. O’Con...

GlobeNewsWire - 6 months ago

$40 million of which came from longtime shareholder, RA Capital Management $40 million of which came from longtime shareholder, RA Capital Management

Zacks Investment Research - 7 months ago

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

Ublituximab was generally well tolerated across all cohorts including those patients receiving one-hour infusions for the 450mg dose currently being studied in the Phase 3 ULTIMATE MS program

GlobeNewsWire - 7 months ago

NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the appointment of Sagar Lonial, MD, FACP, to the Company’s Board of Directors. Dr. Lonial ...

Seeking Alpha - 7 months ago

Today, we update the investment thesis on two oncology concerns whose stocks have been on fire here in April despite the continued COVID-19 outbreak.

Other stocks mentioned: EXEL
Seeking Alpha - 7 months ago

TG Therapeutics: 2020 Offers Investors A Cascade Of Clinical And Regulatory Catalysts

Zacks Investment Research - 8 months ago

TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 8 months ago

NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to umbralis...

Seeking Alpha - 9 months ago

TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q4 2019 Results - Earnings Call Transcript

The Motley Fool - 9 months ago

Acceleron Pharma, Novavax, and TG Therapeutics are all on the cusp of hitting major milestones.

Other stocks mentioned: NVAX, XLRN
Seeking Alpha - 9 months ago

TG Therapeutics: More Catalysts Unlocking

The Motley Fool - 9 months ago

These pharma stocks have gone in different directions in the last year, but both hold promise for forward-thinking investors.

Other stocks mentioned: CARA
GlobeNewsWire - 10 months ago

TG received guidance from the FDA allowing submission of a single NDA for Marginal Zone Lymphoma (MZL) and Follicular Lymphoma indications

Zacks Investment Research - 10 months ago

Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.

The Motley Fool - 10 months ago

These two small-cap biopharmas have promising early-stage drug candidates that could take them far if all goes according to plan.

Other stocks mentioned: FTSV
The Motley Fool - 10 months ago

Two triple-combination therapies delivered impressive results in early-stage studies, which propelled the stock to a 170% gain in 2019.

The Motley Fool - 11 months ago

Risk-taking investors flock to biotech for its constant flow of events that can spike or crush the stock prices of the companies developing the latest therapies.

Other stocks mentioned: ESPR, KPTI
Zacks Investment Research - 11 months ago

TG Therapeutics (TGTX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

GlobeNewsWire - 11 months ago

Company anticipates ending 2019 with approximately $140 million in cash, providing funding well into 2021 Company anticipates ending 2019 with approximately $140 million in cash, providing fun...

Seeking Alpha - 11 months ago

With two pivotal data readouts and potentially three NDA filings coming in the next twelve months, it is time to revisit TG Therapeutics.

About TGTX

TG Therapeutics, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various treatments for B-cell malignancies and autoimmune diseases. The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Its lead therapies include Umbralisib, an investigational dual inhibitor of PI3K delta and CK1 epsilon is being evaluated in phase 2b and phase 3 trials in patients with non-hodgkin lymphoma (NHL) and chronic... [Read more...]

Industry
Biotechnology
IPO Date
Dec 14, 1995
CEO
Michael Weiss
Employees
217
Stock Exchange
NASDAQ
Ticker Symbol
TGTX
Full Company Profile

Financial Performance

In 2019, TGTX's revenue was $152,000, a change of 0.00% compared to the previous year's $152,000. Losses were -$172.87 million, -0.35% less than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price forecast is 47.43, which is an increase of 67.72% from the latest price.

Price Target
$47.43
(67.72% upside)
Analyst Consensus: Strong Buy